Drugs / Nadroparin Calcium
Nadroparin Calcium
also known as
Nadroparin · Fraxiparine · CY 216 · Fraxiparin · Fraxiparina · Nadroparina calcica · Nadroparine calcique · Seleparina · +1 more
Other / unclassified targets SERPINC1 via activation
Trials 22 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 14 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03282643 Comparator | Feb 2016 → Jun 2018 | neoplasm | Capital Medical University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04507178 Comparator | Feb 2022 → Aug 2026 overdue | acquired aneurysmal subarachnoid hemorrhage, brain ischemia | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT04067505 Comparator | May 2020 → Dec 2024 | May-Thurner syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04066764 Comparator | May 2020 → Oct 2024 | venous thromboembolism | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT01431456 Comparator | Sep 2013 → Oct 2014 | venous thromboembolism | Martini Hospital Groningen | Completed | No outcome recorded |
| Phase 3 | NCT01164046 Comparator | Aug 2010 → Jul 2014 | neoplasm, venous thromboembolism | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 3 | NCT00843492 Comparator | Dec 2008 → Jan 2010 | venous thromboembolism | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02238444 Background | Sep 2014 → Sep 2019 | cirrhosis of liver, hypertensive disorder, venous thromboembolism | Yangzhou University | Unknown | No outcome recorded |
| Phase 4 | NCT01828697 Comparator | Apr 2013 → Oct 2021 | pulmonary embolism, venous thromboembolism | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 4 | NCT01531829 Comparator | Jul 2009 → Jul 2012 | pulmonary embolism | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00286273 Comparator | Mar 2003 → Jan 2008 | acute kidney injury | Onze Lieve Vrouwe Gasthuis | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06319131 Comparator | May 2024 → May 2025 | portal vein thrombosis | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT03671174 Background | Aug 2019 → Sep 2021 | habitual spontaneous abortion, undifferentiated connective tissue syndrome | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT02987946 Background | Dec 2016 → Dec 2023 | venous thromboembolism | Leiden University Medical Center | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nadroparin Calcium | “Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous” NCT03671174 ↗7“Nadroparin Calcium and Warfarin” NCT02526303 ↗ |
| Known as | CY 216 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗ |
| Known as | Fraxiparin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗ |
| Known as | Fraxiparina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗ |
| Known as | Fraxiparine | “LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg)...” NCT00796692 ↗3“subcutaneous injection of LMWH, Fraxiparine (n = 23) (0.4 ml, 3800 IU/day) for 2 days” PMID 30903459 ↗ May 2019 “Fraxiparine” NCT02238444 ↗ |
| Known as | Nadroparin | “LMWHs like Nadroparin and Dalteparin are no experimental pharmaceuticals; both have been registered in the Netherlands for these indications since 1989.” NCT01542762 ↗25“50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks” NCT00827554 ↗ “Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days.” NCT01542723 ↗ “nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis” NCT00669721 ↗ “Dalteparin, Enoxaparin, Nadroparin, Tinzaparin” NCT06494878 ↗ “nadroparin 3800-5700IU o.d.” NCT07140211 ↗ “nadroparin” NCT01164046 ↗ “Nadroparin” NCT01531829 ↗ |
| Known as | Nadroparina calcica | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗ |
| Known as | Nadroparine calcique | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗ |
| Known as | Seleparina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗ |
| Known as | Ultraparina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗ |
| Action | Activate | “Antithrombin-III activator” CHEMBL2109204 ↗ |
| Modality | Other / unclassified | “nadroparin is a low molecular weight heparin” NCT00286273 ↗ |
| Route | Subcutaneous | “subcutaneous for 2 weeks” NCT00312013 ↗ |
| Target | SERPINC1 | “Antithrombin-III activator” CHEMBL2109204 ↗ |